在帕金森病的模型中,Acteoside通过防止α-synuclein聚合和氧化应激来发挥神经保护作用
Alessia Lambiase1, Giorgia Spandri2, Hind Moukham2
1Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milano, Italy; National Biodiversity Future Center (NBFC), Palermo, Italy.
概括
研究人员对意大利植物进行了帕金森病查.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 植物学 植物学
背景情况:
- 阿尔法同核素聚合是帕金森病 (PD) 的一个关键特征.
- 开发新的PD治疗策略至关重要.
- 地中海植物提供了丰富的潜在生物活性化合物的来源.
研究的目的:
- 为了识别来自意大利植物的天然化合物,可以抑制α-synuclein聚合.
- 为了探索帕金森病的潜在神经保护剂.
主要方法:
- 在PD的酵母模型中进行基因分析和高通量查.
- 植物提取物的代谢分析.
- 在体外和细胞测定对α-synuclein聚合抑制.
- 生物化学分析 (SEC-MS) 用于识别活性化合物.
- 在体内研究使用Drosophila模型的PD.
主要成果:
- 四种植物物种 (Allium lusitanicum,Salvia pratensis,Verbascum thapsus,Glaucium flavum) 显示出对α-同核素聚合的抑制活性.
- 从Verbascum thapsus中分离出来的化合物actoside直接与α-synuclein结合,并抑制纤维的形成.
- 在细胞模型中,acteoside通过减少氧化应激和激活NRF2通路来显示神经保护作用.
- 在PD的Drosophila模型中,Acteoside改善了运动性能并减少了蛋白质损伤.
结论:
- 乙酸是α-synuclein聚合的强有力的抑制剂,并表现出神经保护性.
- 这项研究突出了Verbascum thapsus及其活性化合物actoside作为新型帕金森病治疗的基础的潜力.
- 这些发现表明,发现神经保护剂的新途径是针对PD相关的氧化应激和蛋白质损伤.
相关概念视频
01:24Parkinson's Disease: Treatment
933
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
933
01:15Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
01:22Alzheimer's Disease: Treatment
744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
01:29Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K